



Novel Models Targetting Vaccines and Drugs for *M. tuberculosis*, *M. avium* and *M. abscessus* Infection

Guest Editors:

Dr. Diane J. Ordway

Mycobacteria Research
Laboratories, Department of
Microbiology, Immunology and
Pathology, Colorado State
University, Fort Collins, CO, USA

Dr. Deepshikha Verma

Mycobacteria Research
Laboratories, Department of
Microbiology, Immunology and
Pathology, Colorado State
University, Fort Collins, CO, USA

Deadline for manuscript
submissions:

closed (22 November 2021)

Message from the Guest Editors

Dear Colleagues,

A deeper understanding of acquired and suppressive immunity against *M. tuberculosis*, *M. avium*, and *M. abscessus* is required to shed light on protective immunity, which may enable effective vaccine and therapeutic compound treatment. The common threads of *Mtb*, *M. avium*, and *M. abscessus* are the ability to infect through aerosol exposure, the increased capacity to develop drug resistance, and the lack of a cure.

These mycobacterial pathogens, *Mtb*, *M. avium*, and *M. abscessus*, are evolving and pose a potential threat to global human health. Novel infection models to understand the mechanisms of immune evasion, new drug regimens, and new vaccines are urgently needed.

Keywords include, but are not limited to:

- *M. tuberculosis*
- *M. avium*
- *M. abscessus*
- novel infection models
- new vaccines and drugs





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology*)

Contact Us

Microorganisms Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI